Flamel Technologies S.A. (ADR) (FLML) Releases Earnings Results, Misses Expectations By $-0.09 EPS

Flamel Technologies S.A. (ADR) (FLML) reported quarterly earnings results on Monday, Aug-8-2016. The company reported $-0.02 earnings per share for the quarter, missing the analyst consensus estimate by $-0.09. Analysts had a consensus of $0.07. The company posted revenue of $38.90 million in the period, compared to analysts expectations of $32.92 million. The company’s revenue was down -20.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.34 EPS.

Flamel Technologies S.A. (ADR) closed down -0.13 points or -1.04% at $12.33 with 1,48,337 shares getting traded on Friday. Post opening the session at $12.57, the shares hit an intraday low of $12.22 and an intraday high of $12.875 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on May 16, 2016, Craig R Stapleton (director) purchased 27,228 shares at $9.23 per share price. According to the SEC, on May 16, 2016, Michael S Anderson (CEO) purchased 5,000 shares at $8.84 per share price. On Mar 22, 2016, Phillandas T. Thompson (officer ) purchased 10,000 shares at $11.10 per share price, according to the Form-4 filing with the securities and exchange commission.

Flamel Technologies SA is a pharmaceutical company. The Company’s focus is on the development of safer and more efficacious formulations and other medical needs in the process. Micropump platform applied to sodium oxybate in a First-in-Man (FIM) clinical study in healthy volunteers. The Company’s products include Bloxiverz and Coreg CR. Bloxiverz (Neostigmine Methylsulfate Injection) is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Coreg CR the lead product using the Company’s Micropump drug delivery platform. Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate) a non-selective antagonist of Beta 1 Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors.

Flamel Technologies S.A. (ADR)

Leave a Reply

Flamel Technologies S.A. (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Flamel Technologies S.A. (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.